ArticleHeliyon2024

The safety and tolerability of a one strength dose-escalation scheme for subcutaneous immunotherapy with a native house dust mite extract in Chinese children: A multicenter, randomized, open label clinical trial.

Lili Zhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.